# Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

> **NCT01935336** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 171 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Extensive Stage Small Cell Lung Cancer
- Limited Stage Small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01935336
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-24
- **Primary completion:** 2017-01
- **Final completion:** 2017-11
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2022-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01935336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01935336, "Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01935336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*